关于临床医学毕业论文的参考文献

  临床医学毕业论文参考文献一

  [1] PORTER J R, RUCKH T T, POPAT K C. Bone tissue engineering: Areview in bone biomimetics and drug delivery strategies [J].Biotechnology progress, 2009, 25:1539-1560.

  [2] KURTZ S M, ONG K L, SCHMIER J, et al. Future clinical and economicimpact of revision total hip and knee arthroplasty [J]. The Journal of boneand joint surgery. American volume, 2007, 89 Suppl 3:144-151.

  [3] XU X, ZHANG K, ZHAO L, et al. Characteristics of three sizes of silicananoparticles in the osteoblastic cell line, MC3T3-E1 [J]. RSC Adv., 2014,4:46481-46487.

  [4] NIE H, HO M L, WANG C K, et al. Bmp-2 plasmid loaded plga/hapcomposite scaffolds for treatment of bone defects in nude mice [J].Biomaterials, 2009, 30:892-901.

  [5] KOLAR P, SCHMIDT-BLEEK K, SCHELL H, et al. The early fracturehematoma and its potential role in fracture healing [J]. Tissue engineering.Part B, Reviews, 2010, 16:427-434.

  [6] ORYAN A, MOSHIRI A, MEIMANDI-PARIZI A. Implantation of anovel tissue-engineered graft in a large tendon defect initiatedinflammation, accelerated fibroplasia and improved remodeling of thenew achilles tendon: A comprehensive detailed study with new insights[J]. Cell and tissue research, 2014, 355:59-80.

  [7] FERGUSON C, ALPERN E, MICLAU T, et al. Does adult fracture repairrecapitulate embryonic skeletal formation? [J]. Mechanisms ofdevelopment, 1999, 87:57-66.

  [8] SIMON A M, MANIGRASSO M B, O'CONNOR J P. Cyclo-oxygenase 2function is essential for bone fracture healing [J]. Journal of bone andmineral research : the official journal of the American Society for Boneand Mineral Research, 2002, 17:963-976.

  [9] DESCHASEAUX F, PONTIKOGLOU C, SENSEBE L. Boneregeneration: The stem/progenitor cells point of view [J]. Journal ofcellular and molecular medicine, 2010, 14:103-115.

  [10] THOMAS M V, PULEO D A. Infection, inflammation, and boneregeneration: A paradoxical relationship [J]. Journal of dental research,2011, 90:1052-1061.

  [11] OFFENBACHER S, ODLE B M, GREEN M D, et al. Inhibition ofhuman periodontal prostaglandin E2 synthesis with selected agents [J].Agents and actions, 1990, 29:232-238.

  [12] OFFENBACHER S, HEASMAN P A, COLLINS J G. Modulation of hostPGE2 secretion as a determinant of periodontal disease expression [J].Journal of periodontology, 1993, 64:432-444.

  [13] PRESHAW P M, HEASMAN P A. Prostaglandin E2 concentrations ingingival crevicular fluid: Observations in untreated chronic periodontitis[J]. Journal of clinical periodontology, 2002, 29:15-20.

  [14] RAISZ L G. Prostaglandins and bone: Physiology and pathophysiology[J]. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society,1999, 7:419-421.

  [15] WILLIAMS R C, JEFFCOAT M K, KAPLAN M L, et al. Flurbiprofen: Apotent inhibitor of alveolar bone resorption in beagles [J]. Science, 1985,227:640-642.

  [16] WILLIAMS R C, JEFFCOAT M K, HOWELL T H, et al. Altering theprogression of human alveolar bone loss with the non-steroidalanti-inflammatory drug flurbiprofen [J]. Journal of periodontology, 1989,60:485-490.

  [17] WEBER H P, FIORELLINI J P, PAQUETTE D W, et al. Inhibition ofperi-implant bone loss with the nonsteroidal anti-inflammatory drugflurbiprofen in beagle dogs. A preliminary study [J]. Clinical oralimplants research, 1994, 5:148-153.

  [18] HARTEN R D, SVACH D J, SCHMELTZER R, et al. Salicylicacid-derived poly(anhydride-esters) inhibit bone resorption and formationin vivo [J]. Journal of biomedical materials research. Part A, 2005,72:354-362.

  [19] REYNOLDS M A, PRUDENCIO A, AICHELMANN-REIDY M E, et al.Non-steroidal anti-inflammatory drug (NSAID) - derived poly(anhydride- esters) in bone and periodontal regeneration [J]. Current drug delivery,2007, 4:233-239.

  [20] FULLER K, CHAMBERS T J. Effect of arachidonic acid metabolites onbone resorption by isolated rat osteoclasts [J]. Journal of bone andmineral research : the official journal of the American Society for Boneand Mineral Research, 1989, 4:209-215.

  临床医学毕业论文参考文献二

  [21] CHAMBERS T J, FOX S, JAGGER C J, et al. The role of prostaglandinsand nitric oxide in the response of bone to mechanical forces [J].Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society,1999, 7:422-423.

  [22] HARDER A T, AN Y H. The mechanisms of the inhibitory effects ofnonsteroidal anti-inflammatory drugs on bone healing: A concise review[J]. Journal of clinical pharmacology, 2003, 43:807-815.

  [23] GERSTENFELD L C, AL-GHAWAS M, ALKHIARY Y M, et al.Selective and nonselective cyclooxygenase-2 inhibitors and experimentalfracture-healing. Reversibility of effects after short-term treatment [J].The Journal of bone and joint surgery. American volume, 2007,89:114-125.

  [24] VUOLTEENAHO K, MOILANEN T, MOILANEN E. Non-steroidalanti-inflammatory drugs, cyclooxygenase-2 and the bone healing process[J]. Basic & clinical pharmacology & toxicology, 2008, 102:10-14.

  [25] HAVEMOSE-POULSEN A, HOLMSTRUP P. Factors affectingil-1-mediated collagen metabolism by fibroblasts and the pathogenesis ofperiodontal disease: A review of the literature [J]. Critical reviews in oralbiology and medicine : an official publication of the AmericanAssociation of Oral Biologists, 1997, 8:217-236.

  [26] GRAVES D. Cytokines that promote periodontal tissue destruction [J].Journal of periodontology, 2008, 79:1585-1591.

  [27] MOUNTZIARIS P M, MIKOS A G. Modulation of the inflammatoryresponse for enhanced bone tissue regeneration [J]. Tissue engineering.Part B, Reviews, 2008, 14:179-186.

  [28] GERSTENFELD L C, CHO T J, KON T, et al. Impairedintramembranous bone formation during bone repair in the absence oftumor necrosis factor-alpha signaling [J]. Cells, tissues, organs, 2001,169:285-294.

  [29] JANSSENS S, BEYAERT R. Functional diversity and regulation ofdifferent interleukin-1 receptor-associated kinase (irak) family members[J]. Molecular cell, 2003, 11:293-302.

  [30] BOYCE B F, XING L, FRANZOSO G, et al. Required and nonessentialfunctions of nuclear factor-kappa B in bone cells [J]. Bone, 1999,25:137-139.

  [31] CHANG J, WANG Z, TANG E, et al. Inhibition of osteoblastic boneformation by nuclear factor-kappa B [J]. Nature medicine, 2009,15:682-689.

  [32] TABAS I, GLASS C K. Anti-inflammatory therapy in chronic disease:Challenges and opportunities [J]. Science, 2013, 339:166-172.

  [33] WIMALAWANSA S J. Nitric oxide: Novel therapy for osteoporosis [J].Expert opinion on pharmacotherapy, 2008, 9:3025-3044.

  [34] WIMALAWANSA S J. Nitric oxide and bone [J]. Annals of the New YorkAcademy of Sciences, 2010, 1192:391-403.

  [35] BIGHAM-SADEGH A, ORYAN A. Basic concepts regarding fracturehealing and the current options and future directions in managing bonefractures [J]. International wound journal, 2014.

  [36] MARSELL R, EINHORN T A. The role of endogenous bonemorphogenetic proteins in normal skeletal repair [J]. Injury, 2009, 40Suppl 3:S4-7.

  [37] ORYAN A, ALIDADI S, MOSHIRI A, et al. Bone morphogeneticproteins: A powerful osteoinductive compound with non-negligible sideeffects and limitations [J]. BioFactors, 2014, 40:459-481.

  [38] REDLICH K, SMOLEN J S. Inflammatory bone loss: Pathogenesis andtherapeutic intervention [J]. Nature reviews. Drug discovery, 2012,11:234-250.

  [39] GARIMELLA R, TAGUE S E, ZHANG J, et al. Expression and synthesisof bone morphogenetic proteins by osteoclasts: A possible path toanabolic bone remodeling [J]. The journal of histochemistry andcytochemistry : official journal of the Histochemistry Society, 2008,56:569-577.

  [40] COTTRELL J A, KEANE O, LIN S S, et al. BMP-2 modulatesexpression of other growth factors in a rat fracture healing model [J].Journal of Applied Biomedicine, 2014, 12:127-135.

相关推荐